Pridopidine hydrochloride is under clinical development by Prilenia Therapeutics Development and currently in Phase III for Huntington Disease. According to GlobalData, Phase III drugs for Huntington Disease have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pridopidine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pridopidine hydrochloride overview
Pridopidine hydrochloride (ACR-16, Huntexil, ASP-2314) is under development for the treatment of Huntington disease, amyotrophic lateral sclerosis, neurodegenerative eye disease, Parkinson’s disease, Rett syndrome, fragile X syndrome, Alzheimer's disease, vanishing white matter disease and wolfram syndrome. The drug candidate is administered orally in the form of capsule. It acts by targeting dopamine receptor D2 and sigma-1 receptor.
It was also under development for the treatment of motor disorders including schizophrenia and Parkinson’s disease levodopa induced dyskinesia (PD-LID).
Prilenia Therapeutics Development overview
Prilenia Therapeutics Development (Prilenia) is a biotechnology company that develops therapies to treat neurobehavioral disorders and neurodegenerative diseases in adults and children. The company is investigating its lead product candidate Pridopidine, a small molecule drug against Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and dyskinesia associated with levodopa drug which is used to treat Parkinson’s disease. It is also evaluating its lead product to treat neurodegenerative eye diseases, Parkinson’s disease, Rett syndrome, Fragile X syndrome, and Alzheimer’s disease. Prilenia funding partners include Forbion Capital Partners, Talisman Capital Partners, Morningside Ventures and Sectoral Asset Management. The company has an operational presence in the Netherlands. Prilenia is headquartered in Herzliya, Tel Aviv, Israel.
For a complete picture of Pridopidine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
